Related Experiment Video
Updated: Jun 15, 2026
Transmitochondrial Cybrid Generation Using Cancer Cell Lines
Published on: March 17, 2023
Targeting mitochondria for cancer therapy
1Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. dhockenb@fhcrc.org
Abstract:
Several recent insights into the roles of mitochondria in cancer have renewed efforts to develop nongenotoxic therapies targeting mitochondrial proteins and functions. Mitochondria are central hubs for intrinsic apoptotic pathways that are activated by cellular stress and injury, and as a consequence, cancers often have defects in these pathways. Bcl-2, the first identified regulator of apoptotic cell deaths, was discovered as an oncogene in human cancers. BCL-2 inhibits mitochondrial pathways of apoptosis through local effects at mitochondrial and endoplasmic reticulum membranes. Increased expression of BCL-2 and the related antiapoptotic proteins BCL-X(L), MCL-1, and BCL-W occurs in significant subsets of common cancer types (Table I) and is generally correlated with poor response. Although incomplete, the emerging understanding of BCL-2 functions through structural, biochemical, and organelle physiology studies has provided paths for targeting BCL-2 with small molecules. Cancer cells also exhibit metabolic differences with their normal cell counterparts, including aerobic glycolysis, known as the Warburg effect, mitochondrial membrane hyperpolarization, and unusual dependence on nutrient substrates such as glucose and glutamine. This knowledge has prompted reexamination of the potential cancer selectivity of previously identified mitochondriotoxic compounds, including approved drugs for other indications, and screening programs to identify new compounds with mitochondrial activities.
Insights
Targeting cancer cell mitochondria, particularly the anti-apoptotic protein BCL-2, offers a promising nongenotoxic therapy strategy. Research explores targeting mitochondrial functions and metabolic vulnerabilities for novel cancer treatments.
Area of Science:
- Mitochondrial biology and cancer therapeutics
- Molecular mechanisms of apoptosis regulation
- Cancer cell metabolism
Background:
- Mitochondria are crucial in cancer due to defects in apoptotic pathways.
- The anti-apoptotic protein BCL-2 is often overexpressed in cancers, correlating with poor treatment response.
- Cancer cells exhibit distinct metabolic profiles, including the Warburg effect and altered nutrient dependencies.
Purpose of the Study:
- To explore nongenotoxic therapeutic strategies targeting mitochondrial proteins and functions in cancer.
- To investigate the potential of targeting BCL-2 and related anti-apoptotic proteins with small molecules.
- To re-evaluate mitochondriotoxic compounds and screen for new agents based on cancer cell metabolic vulnerabilities.
Main Methods:
- Review of recent insights into mitochondrial roles in cancer.
- Analysis of structural, biochemical, and physiological studies on BCL-2 function.
- Reexamination of known mitochondriotoxic compounds and screening for novel agents.
Main Results:
- BCL-2 and related proteins (BCL-X(L), MCL-1, BCL-W) are frequently upregulated in cancers, inhibiting apoptosis.
- Understanding BCL-2's function provides avenues for small molecule drug development.
- Cancer-specific metabolic differences suggest potential for targeted therapies using mitochondriotoxic compounds.
Conclusions:
- Targeting mitochondrial pathways, especially BCL-2, represents a viable nongenotoxic cancer therapy approach.
- Exploiting cancer cell metabolic vulnerabilities can enhance the efficacy of mitochondriotoxic agents.
- Further research into mitochondrial-targeted therapies holds significant promise for improved cancer treatment outcomes.
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...